Highlights Jaguar Health, Inc.

Equities

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 12/02/2026 am IST			5-day change	1st Jan Change
0.6070 ^USD	-5.45%		+4.66%	-34.82%

16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI

Highlights

21/11	Sector Update: Health Care Stocks Softer Late Afternoon	MT
17/11	Gastrointestinal drugmaker Jaguar Health's Q3 net loss narrows	RE
15/11	Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
04/25/04	Jaguar Health files for resale of up to 2.6 million shares by selling stockholders - SEC filing	RE
02/25/02	Jaguar Health says on September 28 entered securities purchase agreement with Brown Stone Capital Limited - SEC filing	RE
24/25/24	Jaguar Health Unit Submits Orphan Drug Status Application to US FDA for Cancer Therapy-Related Diarrhea Drug	MT
15/25/15	Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/25/21	Jaguar Health Prices Offering of Shares, Warrants	MT
15/25/15	Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
30/25/30	Jaguar Health, Inc. and Napo Therapeutics Announce Initial Proof-Of-Concept Results	CI
31/25/31	Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/24/13	Earnings Flash (JAGX) JAGUAR HEALTH Posts Q3 Revenue $3.1M	MT
13/24/13	Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
06/24/06	FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs	CI
24/24/24	Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024	CI
27/24/27	Jaguar Health Awarded Patent in Jordan for Short Bowel Syndrome Treatment	MT
19/24/19	Jaguar Health Reports Issue of Hong Kong Patent for Short Bowel Syndrome Treatment Methods	MT
19/24/19	Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome	CI
13/24/13	Earnings Flash (JAGX) JAGUAR HEALTH Reports Q2 Revenue $2.7M, vs. Street Est of $3.4M	MT
13/24/13	Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
05/24/05	Jaguar Health to Detail Regulatory Strategy for Antidiarrheal Drug for Cancer Patients Next Week	MT
31/24/31	Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders	CI
23/24/23	Top Midday Decliners	MT
23/24/23	Sector Update: Health Care Stocks Advance in Afternoon Trading	MT
23/24/23	Jaguar Health Shares Plunge After Cancer Therapy-Related Diarrhea Treatment Fails to Meet Primary Goal	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Jaguar Health, Inc.

Equities

JAGX

US47010C8881

Pharmaceuticals

Highlights

Filters